IP Library Granted Patent US 8,288,145
Granted Patent B2
US 8,288,145 · App. 12/444,248 · Granted Oct 16, 2012

Medium supplement for virus production

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,288,145
App. No.
12/444,248
Granted
Oct 16, 2012
Kind
B2
Abstract

The use of macrolide polyene antibiotics or derivatives or analogues thereof as culture supplement for the propagation of virus is described. Further pharmaceutical compositions comprising a virus and a macrolide polyene antibiotic or a derivative or analogue thereof and methods for using of macrolide polyene antibiotics for transfection and infection of cells as well as the use of macrolide polyene antibiotics for the isolation of virus from clinical samples are disclosed.

Claims (18)

1. A method of propagating influenza virus, comprising the step of adding amphotericin B to a cell culture comprising VERO cells and the influenza virus.

2. The method of claim 1 , wherein the amphotericin B is added to the cell culture at a concentration of between 0.5 ng/ml and 5 microg/ml.

3. The method of claim 2 , wherein the amphotericin B is at a concentration of between 0.5 ng/ml and 2.5 μg/ml.

4. The method of claim 3 , wherein the amphotericin B is at a concentration of between 10 ng/ml and 900 ng/ml.

5. The method of claim 4 , wherein the amphotericin B is at a concentration of between 100 ng/ml and 500 ng/ml.

6. The method of claim 5 , wherein the amphotericin B is at a concentration of between 200 ng/ml and 400 ng/ml.

7. The method of claim 1 , wherein the influenza virus is selected from the group consisting of influenza A virus, influenza B virus, and influenza C virus.

8. The method of claim 1 , wherein the influenza virus contains a modification within the NS1 or PB1 gene.

9. The method of claim 8 , wherein the modification is a deletion, substitution or insertion of at least one nucleic acid.

10. The method of claim 1 wherein virus growth in the cell culture is increased compared to virus growth in the absence of amphotericin B by an amount of at least 0.1 log 10, preferably at least 0.5 log 10, more preferably at least 1 log 10, more preferably at least 2 log 10, and even more preferably at least 2.5 log 10.

11. A method of transfecting Vero cells, comprising the step of adding amphotericin B to a cell culture comprising Vero cells before, simultaneously with or shortly after transfecting the Vero cells with expression plasmids containing viral RNA segments of influenza virus.

12. A method for the infection of cells for influenza virus cultivation using amphotericin B, comprising the following steps:

a) infecting cells with at least one infectious influenza virus particle;

b) adding at least amphotericin B to an inoculum or cultivation media together with trypsin to form a cell culture mixture;

c) incubating the cells with the cell culture mixture; followed by

d) harvesting of influenza viruses.

13. The method of claim 12 , further comprising the step of purifying the harvested virus.

14. The method of claim 12 , further comprising the step of characterizing the harvested virus.

Assignments (9)
CHANGE OF NAME Recorded Nov 20, 2025
From: RESILIENCE GOVERNMENT SERVICES, INC,
To: ALACHUA GOVERNMENT SERVICES, INC.
Reel/Frame 073279/0021 →
CHANGE OF NAME Recorded Sep 8, 2022
From: OLOGY BIOSERVICES, INC.
To: RESILIENCE GOVERNMENT SERVICES, INC.
Reel/Frame 061399/0903 →
RELEASE OF SECURITY INTEREST Recorded Aug 20, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: OLOGY BIOSERVICES, INC.; NANO ADM, LLC
Reel/Frame 053561/0070 →
CHANGE OF NAME Recorded Jan 23, 2019
From: NANOTHERAPEUTICS, INC.
To: OLOGY BIOSERVICES, INC.
Reel/Frame 048117/0275 →
SECURITY INTEREST Recorded May 1, 2018
From: OLOGY BIOSERVICES, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 046050/0305 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRESPONDENCE DATA PREVIOUSLY RECORDED ON REEL 037155 FRAME 0732. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 2, 2016
From: BAXALTA GMBH
To: NANOTHERAPEUTICS, INC.
Reel/Frame 038592/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2015
From: BAXALTA GMBH
To: NANOTHERAPEUTICS, INC.
Reel/Frame 037155/0732 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH
Reel/Frame 036388/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2013
From: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AG
To: BAXTER HEALTHCARE SA
Reel/Frame 030034/0893 →